复合益生菌对非透析慢性肾脏病患者微炎症状态及肾功能的影响  

Effects of compound probiotics on microinflammatory status and renal function in patients with nondialysis chronic kidney disease

作　　者：管红斌[1] 吕路[1] 何凯平[2] GUAN Hong-bin;LYU Lu;HE Kai-ping(Department of Nephrology,First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510080,China)

机构地区：[1]广东药科大学附属第一医院肾内科,510080 [2]广东药科大学附属第一医院病案统计科,510080

出　　处：《中国现代药物应用》2022年第13期6-9,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨复合益生菌对非透析慢性肾脏病(CKD)患者微炎症状态及肾功能的影响。方法58例非透析CKD患者,采用随机数字表法分为对照组和益生菌组,每组29例。对照组给予CKD基础治疗,观察组在对照组基础上给予复合益生菌治疗。比较两组患者治疗前后微炎症指标[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、血清淀粉样蛋白A(SAA)]、肾功能指标[血清肌酐(SCr)、尿素氮(BUN)]及不良反应发生情况。结果治疗后,两组患者hs-CRP、IL-6、SAA水平均低于治疗前,且益生菌组hs-CRP(6.98±2.36)mg/L、IL-6(13.47±3.67)pg/ml、SAA(7.17±3.12)mg/L均低于对照组的(9.86±3.24)mg/L、(17.58±4.16)pg/ml、(9.36±3.11)mg/L,差异均有统计学意义(P<0.05)。治疗后,对照组患者SCr、BUN水平均低于治疗前,但差异均无统计学意义(P>0.05);治疗后,益生菌组患者SCr(102.33±31.29)μmol/L、BUN(9.36±0.32)mmol/L均低于本组治疗前的(129.45±38.36)μmol/L、(10.07±0.31)mmol/L和对照组治疗后的(120.39±33.47)μmol/L、(9.82±0.36)mmol/L,差异均有统计学意义(P<0.05)。结论非透析CKD患者体内存在微炎症状态,补充复合益生菌可降低非透析CKD患者血清炎症因子水平,改善微炎症状态及肾功能。Objective To discuss the effects of compound probiotics on microinflammatory status and renal function in patients with non-dialysis chronic kidney disease(CKD).Methods A total of 58 cases of non-dialysis CKD patients were divided into control group and probiotic group by random numerical table,with 29 cases in each group.The control group received CKD basic treatment,and the observation group received compound probiotics treatment on the basis of the control group.Both groups were compared in terms of microinflammatory indexes[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),serum amyloid A(SAA)]and renal function indexes[serum creatinine(SCr),blood urea nitrogen(BUN)]before and after treatment,and occurrence of adverse reactions.Results After treatment,the levels of hs-CRP,IL-6 and SAA in the two groups were lower than those before treatment in this group;the hs-CRP(6.98±2.36)mg/L,IL-6(13.47±3.67)pg/ml,SAA(7.17±3.12)mg/L in the probiotic group was lower than(9.86±3.24)mg/L,(17.58±4.16)pg/ml,(9.36±3.11)mg/L in the control group;all the differences were statistically significant(P<0.05).After treatment,the levels of SCr and BUN in the control group were lower than those before treatment,but the difference was not statistically significant(P>0.05).After treatment,the SCr(102.33±31.29)μmol/L and BUN(9.36±0.32)mmol/L in the probiotic group were lower than(129.45±38.36)μmol/L and(10.07±0.31)mmol/L before treatment in this group,and(120.39±33.47)μmol/L and(9.82±0.36)mmol/L in the control group.All the differences were statistically significant(P<0.05).Conclusion There is a micro-inflammatory status in non-dialysis CKD patients,and supplementation of compound probiotics can reduce the level of serum inflammatory factors and improve the micro-inflammatory status and renal function in non-dialysis CKD patients.

关 键 词：复合益生菌 慢性肾脏病 微炎症状态 肾功能 

分 类 号：R692[医药卫生—泌尿科学]